Fulgent Genetics, Inc. (FLGT), a technology-driven precision medicine company, reported solid financial results for the first quarter of 2025, with strong performance in its core laboratory services business and continued investment in its therapeutic pipeline.
The California-based company provides advanced laboratory testing services and is developing targeted cancer therapies through its proprietary nanoencapsulation platform.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com